Research programme: cell therapies - Juno Therapeutics/MSKCC/Eureka

Drug Profile

Research programme: cell therapies - Juno Therapeutics/MSKCC/Eureka

Latest Information Update: 08 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Juno Therapeutics
  • Class Antineoplastics; CAR-T cell therapies
  • Mechanism of Action T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Research Multiple myeloma

Most Recent Events

  • 06 Dec 2017 Juno Therapeutics and Eli Lilly agree to develop crenigacestat, in combination with BCMA-directed CAR T cell therapies, for Multiple myeloma )
  • 06 Dec 2017 Juno Therapeutics in-licenses rights to intellectual property using gamma secretase inhibitors, in combination with BCMA-directed CAR T cell therapy from OncoTracker and Fred Hutchinson Cancer Research Center
  • 06 Dec 2017 Juno Therapeutics plans a clinical trial for Multiple myeloma (Combination therapy) in 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top